2. Search Result
Search Result
Results for "

RNA polymerase β-subunit

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13234
    Rifaximin
    5+ Cited Publications

    		 Bacterial Antibiotic DNA/RNA Synthesis Infection Cancer
    Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL) .
    Rifaximin
  • HY-105099
    Rifalazil

    KRM-1648; ABI-1648

    		 Antibiotic DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .
    Rifalazil
  • HY-135751
    Holomycin

    		Antibiotic Bacterial DNA/RNA Synthesis Infection Cancer
    Holomycin is an antibiotic with dithiolopyrrolone structure. Holomycin can inhibit bacterial RNA synthesis. Holomycin has antitumor activity. Holomycin can be used for the research of bacterial infection .
    Holomycin
  • HY-153696
    MRL-436

    		DNA/RNA Synthesis Bacterial Infection
    MRL-436 is a RNA polymerase inhibitor with antibacterial activity. MRL-436 exerts its antibacterial activity dependent on residue 622 of the RNA polymerase β' subunit and the RNAP ω subunit. MRL-436 inhibits Rifampicin (HY-B0272)-resistant RNA polymerase derivatives and exhibits antibacterial activity against Rifampicin-resistant strains .
    MRL-436
  • HY-13234R
    Rifaximin (Standard)

    		Reference Standards Bacterial Antibiotic DNA/RNA Synthesis Infection Cancer
    Rifaximin (Standard) is the analytical standard of Rifaximin. This product is intended for research and analytical applications. Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL) .
    Rifaximin (Standard)
  • HY-105099R
    Rifalazil (Standard)

    KRM-1648 (Standard); ABI-1648 (Standard)

    		 Antibiotic Reference Standards DNA/RNA Synthesis Bacterial Infection Inflammation/Immunology
    Rifalazil (Standard) is the analytical standard of Rifalazil. This product is intended for research and analytical applications. Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase[1]. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml[3]. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB)[2].
    Rifalazil (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: